ADRIATIC study: New standard of care treatment for small cell lung cancer

Join the Oncology Brothers, Rahul and Rohit Gosain, in this insightful podcast episode as they dive into the world of small cell lung cancer with special guest Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center.

Key Points:
•⁠ ⁠The Adriatic study's impact on improving survival with Durvalumab in limited-stage disease.
•⁠ ⁠Treatment options for extensive-stage disease, including second-line therapies like Lurbinectedin and the recent approval of Tarlatamab.
•⁠ ⁠The significance of individualized treatment decisions and ongoing research in small cell lung cancer management.

In this episode, Dr. Singhi discusses the management of limited-stage small cell lung cancer, the impact of the recent Adriatic study on treatment approaches, and the use of immunotherapy in both limited and extensive-stage disease. The conversation also delves into the role of PCI, the use of Trilaciclib in extensive stage, and the recent FDA approval of Tarlatamab for small cell lung cancer.

Discover the latest advancements and treatment options for small cell lung cancer, including insights on second-line treatments, consolidation radiation, and the management of patients with driver mutations. Dr. Singhi also highlights the importance of patient advocacy groups like the Small Cell Smashers in providing support for individuals with small cell lung cancer.

Tune in to this episode for a comprehensive overview of the current treatment landscape for small cell lung cancer and gain valuable insights from Dr. Singhi's expertise in the field. Don't miss out on this informative discussion on the Oncology Brothers podcast!